NASDAQ:ACIU
AC Immune SA Stock News
$3.18
-0.230 (-6.74%)
At Close: May 17, 2024
Immunotherapy Pioneer Prof. Carl H. June Joins AC Immune's Board of Directors
08:40am, Friday, 20'th Nov 2020
Prof. June is a world authority on immune tolerance and adoptive immunotherapy
Neurologist and Psychiatrist Prof. Johannes Rolf Streffer, MD Joins AC Immune SA as Chief Medical Officer
07:00am, Wednesday, 18'th Nov 2020
Prof. Streffer is a n established authority on n euroscience and b iomarker modalities
AC Immune: Q3 Earnings Insights
07:27am, Friday, 13'th Nov 2020
Shares of AC Immune (NASDAQ:ACIU) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were down 204.00% over the past year to ($0.26), which beat the estima
AC Immune Reports Q3 2020 Financial Results and Provides Business Update
07:00am, Friday, 13'th Nov 2020
LAUSANNE, Switzerland, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative disease
Strategic partnership reflects AC Immune's growing expertise in monoclonal antibody development Strategic partnership reflects AC Immune's growing expertise in monoclonal antibody development
AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma
04:44am, Friday, 30'th Oct 2020
AC Immune suffers setback on Alzheimer's front. Galera Therapeutics provides positive update of GC4419 in pancreatic cancer.
Aerie (AERI) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
02:53pm, Friday, 07'th Aug 2020
Aerie (AERI) posts a wider-than-expected loss and sales miss estimates in the second quarter of 2020.
All You Need to Know About AC Immune (ACIU) Rating Upgrade to Strong Buy
04:00pm, Thursday, 06'th Aug 2020
AC Immune (ACIU) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AC Immune (ACIU) Reports Q2 Loss, Tops Revenue Estimates
03:25pm, Wednesday, 05'th Aug 2020
AC Immune (ACIU) delivered earnings and revenue surprises of 25.00% and 215.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
AC Immune Reports Q2 2020 Financial Results and Provides Business Update
11:00am, Wednesday, 05'th Aug 2020
* Substantial progress achieved across three anti-Tau clinical development programs; all clinical and preclinical programs remain on track to generate value in the second half of 2020 * Top line Phas
AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegeneration
11:00am, Monday, 03'rd Aug 2020
First-in-class TDP-43 antibody developed using SurpraAntigen™ platform The only TDP-43 antibody with reported in vivo activity LAUSANNE, Switzerland, Aug. 03, 2020 (GLOBE NEWSWIRE) -- AC Immune S
AC Immune Wins Prestigious Award to Develop a “Game-Changing” Parkinson’s Diagnostic Tool
11:55am, Thursday, 30'th Jul 2020
AC Immune is one of three winners sharing USD 10 million through The Michael J. Fox Foundation Ken Griffin Alpha-synuclein Imaging Competition The award follows compelling preclinical results prese
AC Immune Demonstrates Enhanced Performance of First-in-class Parkinson’s Diagnostic Agent
11:00am, Tuesday, 28'th Jul 2020
Next-generation PET tracer detects pathological alpha-synuclein with improved signal-to-noise ratio Oral presentation at AAIC further demonstrates the strength of AC Immune’s Morphomer™ platform
Presentations to highlight the Company’s broad expertise addressing both novel and well-established targets in neurodegenerative diseasesLAUSANNE, Switzerland, July 23, 2020 (GLOBE NEWSWIRE) -- AC I
AC Immune Advances Alzheimer's Vaccine to Phase Ib/IIa Study
02:04pm, Friday, 17'th Jul 2020
AC Immune (ACIU) advances its Alzheimer's disease vaccine, ACI-35.030, to phase Ib/IIa study.
